Castle Biosciences CCO Tobin W. sells $222,620 in shares
FRIENDSWOOD, TX – Castle Biosciences Inc. (CSTL) recently reported a notable insider sale by its Chief Commercial Officer, Tobin W. Juvenal. On September 14, 2026, Juvenal sold 3,306 shares of the company's common stock, valued at $222,620, at a weighted-average price of $32.324 per share. This brought his direct ownership down to 61,878 shares.
The following day, he sold an additional 3,294 shares at a higher weighted-average price of $35.142, reducing his direct ownership to 58,584 shares. This sale of 6,600 shares came as Castle Biosciences' stock price surged 77% over the past six months, currently trading at $33.79 with a market capitalization of $1.04 billion. The stock is also trading near its Fair Value, according to InvestingPro analysis.
The transactions were executed under a Rule 10b5-1 trading plan adopted by Juvenal on May 28, 2026. Recently, the company reported its third-quarter results, surpassing Wall Street expectations with an adjusted loss of $0.13 per share, compared to the projected $0.35 loss per share. Revenue increased by 24% to $102.9 million, exceeding the forecasted $92.41 million.
These positive developments have attracted investor and analyst attention, alongside Castle Biosciences' updated full-year revenue outlook.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
